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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.03.003A34-year-old male presented with a 2-monthhistory of fever, backache, and generalizedrash. Clinical examination revealed general-
ized lymphadenopathy along with maculopapular,
erythematous, conﬂuent rash involving the face, trunk,
and extremities. Complete blood counts showed
pancytopenia (hemoglobin 8.1 g/dL, platelet count
7000/mm3, and white blood cell count 2000/mm3).
Bone marrow examination revealed intermediate to
large sized blasts. The blast population expressedCD4, CD56, HLA-DR, dim to negative CD38 and
CD45 and variable CD123. Blasts did not express
CD 303, markers of myeloid, B-cell or T-cell lineage.
The morphological and immunophenotypic ﬁndings
were consistent with a diagnosis of blastic plasmacy-
toid dendritic cell neoplasm (BPDCN). BPDCN
is a rare malignancy, and belongs to the category of
acute myeloid leukemia and related precursor
neoplasms. It commonly affects elderly males and
involves skin, bone marrow and lymph nodes. The97
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blasts have abundant cytoplasm with a low nuclear-to-
cytoplasmic ratio with microvacuoles beneath the
nuclear membrane. They co-express CD4 and
CD56 without common lymphoid or myeloid lineage
markers. They may express CD 123, TCL1, CD 303,
CD2AP, and the IL-3 receptor a-chain. Curative
treatment options are limited and include acute
lymphoblastic or myeloid leukemia-like induction che-
motherapy followed by allogeneic stem cell transplant.HemaCONFLICT OF INTEREST
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